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Abstract 
We recently showed that IL-6-type cytokine signaling in adipocytes induces FFA 
release from visceral adipocytes thereby promoting obesity-induced hepatic insulin 
resistance and steatosis. In addition, IL-6-type cytokines may increase the release of 
leptin from adipocytes and by that means induce GLP-1 secretion. We thus 
hypothesized that IL-6-type cytokine signaling in adipocytes may regulate insulin 
secretion. To this end, mice with adipocyte-specific knockout of gp130, the signal 
transducer protein of IL-6, were fed a high fat diet for 12 weeks. Compared to control 
littermates, knockout mice showed impaired glucose tolerance and circulating leptin, 
GLP-1 and insulin levels were reduced. In line, leptin release from isolated adipocytes 
was reduced and intestinal Pcsk1 expression, the gene encoding PC1/3, which controls 
GLP-1 production, was decreased in knockout mice. Importantly, treatment with the 
GLP-1 receptor antagonist exendin 9-39 abolished the observed difference in glucose 
tolerance between control and knockout mice. Ex vivo, supernatant collected from 
isolated adipocytes of gp130 knockout mice blunted Pcsk1 expression and GLP-1 
release from GLUTag cells. In contrast, glucose and GLP-1 stimulated insulin secretion 
was not affected in islets of knockout mice. In conclusion, adipocyte-specific IL-6 
signaling induces intestinal GLP-1 release to enhance insulin secretion thereby 
counteracting insulin resistance in obesity. 
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Introduction 
High production and release of interleukin-6 (IL-6) from adipose tissue may 
contribute to dys-regulated metabolism in obesity and, thus, contribute to the 
development of insulin resistance (1-3). Consistently, we recently reported a role of IL-6 
signaling in adipocytes in the development of obesity-associated liver insulin resistance 
and steatosis by making use of adipocyte-specific glycoprotein 130 (gp130) knockout 
(gp130Δadipo) mice (4). gp130 is a common signal transducer protein of all IL-6-type 
cytokines which comprises eight different cytokines such as IL-6, interleukin 11 (IL-11) 
and leukemia inhibitor factor (LIF) (5). It was previously suggested that these IL-6-type 
cytokines may impact on leptin production in adipose tissue (6-8), thereby potentially 
mediating a protective effect on glucose metabolism. Interestingly, leptin was found to 
stimulate the release of glucagon-like peptide-1 (GLP-1) from enteroendocrine cells (9). 
GLP-1 is an important inducer of glucose-stimulated insulin release in vivo and it also 
inhibits gastric emptying and glucagon secretion (10). Hence, identification of factors 
promoting endogenous GLP-1 release is of interest since enhancing endogenous GLP-1 
secretion may be a useful strategy to prevent pancreatic β-cell failure in insulin-resistant 
obese patients and subsequent development of type 2 diabetes (11). Active GLP-1 is 
mainly secreted into circulation from intestinal L cells after being cleaved from its 
precursor proglucagon by the prohormone convertase 1/3 (PC1/3) (10; 12; 13). The 
latter is encoded by proprotein convertase subtilisin/kexin type 1 (Pcsk1) that is 
expressed in intestinal L cells as well as alpha cells of pacreatic islets (13). Accordingly, 
GLP-1 can also be produced in pancreatic islets where it shows paracrine actions (12). 
In fact, it has recently been proposed that GLP-1 originating from pancreatic islets may 
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be more important for glucose homeostasis than GLP-1 produced in intestinal L cells 
(14; 15).  
In the present study, we hypothesized that adipocyte-specific IL-6-type cytokine 
signaling induces leptin-mediated GLP-1 release in obese mice thereby improving 
glucose-stimulated insulin release and glucose tolerance. 
 
 
Research Design and Methods 
Animals 
Adipocyte-specific gp130 knockout mice (gp130adipo) on a C57BL/6J background 
were generated by crossing gp130 floxed (gp130F/F) mice (16) with animals expressing 
the Cre recombinase controlled by the Adipoq promoter (AdipoqCre mice; purchased 
from The Jackson Laboratory, Bar Harbor, ME, USA). Six weeks-old male mice were fed 
ad libitum with standard rodent diet (chow) or high fat diet (HFD; D12331, Research 
Diets, New Brunswick, USA) for 12 weeks. HFD consisted of 58% of calories derived 
from fat, 28% from carbohydrate and 16% from protein. All protocols conformed to the 
Swiss animal protection laws and were approved by the Cantonal Veterinary Office in 
Zurich, Switzerland.  
 
Intraperitoneal glucose and insulin tolerance test 
Intraperitoneal glucose and insulin tolerance tests were performed as described 
(17). To block GLP-1 action, exendin 9-39 (25 nM/kg body weight; Bachem, Bubendorf, 
Switzerland), was injected intraperitoneally 1 minute prior to glucose injection. Blood 
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glucose concentration was measured in blood from tail-tip bleedings using a glucometer 
(AccuCheck Aviva, Roche Diagnostics, Rotkreuz, Switzerland). 
 
Oral glucose tolerance test 
Glucose (2g/kg body weight) was orally administered in overnight fasted mice. To 
block GLP-1 action, exendin 9-39 (25 nM/kg body weight), was injected intraperitoneally 
15 minutes prior to oral glucose administration. Blood glucose concentration was 
measured in blood from tail-tip bleedings using a glucometer (AccuCheck Aviva). 
 
Food intake 
Food intake was determined using a metabolic and behavioral monitoring system 
(PhenoMaster, TSE Systems, Bad Homburg, Germany) as described (18). 
 
Leptin release from isolated adipocytes 
Adipocytes were isolated as described (19). Isolated adipocytes were incubated 
in the absence or presence of 1 nM/l CNTF (BioLegend, San Diego, CA, USA), 1 nM/l 
CT-1 (BioLegend), 5 nM/l recombinant IL-6 (AdipoGen), 10 nM/l IL-11 (Lucerna Chem, 
Luzern, Switzerland), 2.5 nM/l LIF (Miltenyi Biotec, Bergisch Gladbach, Germany) or 1 
nM/l OSM (BioLegend) for four hours. Leptin levels were measured using MSD 
technology (Meso Scale Discovery, Gaithersburg, MD, USA). 
 
Blood sampling 
To prevent GLP-1 degradation, sitagliptine (25µg/g body weight; Sigma, Buchs, 
Switzerland) was injected intraperitoneally 30 minutes before oral or intraperitoneal 
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glucose administration. Of note, sitagliptine was demonstrated to increase circulating 
GLP-1 levels in mice (20). EDTA (5mM) and Diprotin A (0.1 mM; Sigma) were added to 
the collected blood followed by immediate centrifugation at 4°C and plasma was stored 
at -80°C until further processing. 
 
Determination of plasma parameters 
Plasma active GLP-1 and leptin were determined using MSD technology. Plasma 
insulin levels were measured using an ELISA kit as described previously (21). ELISA 
kits were used to measure plasma adiponectin (AdipoGen, Liestal, Switzerland), DPP IV 
(Abnova, Taipei City, Taiwan) and IL-6 (BioLegend, San Diego, CA, USA).  
 
RNA extraction and quantitative reverse transcription-PCR (RT-PCR) 
Total RNA was extracted (NucleoSpin, Macherey-Nagel, Düren, Germany) and 
concentration was determined spectrophotometrically (Nanodrop 1000; Nanodrop 
Technologies, Boston, MA). RNA was reverse transcribed with GoScript Reverse 
Transcription System (Promega, Madison, WI, USA). Taqman assays (Applied 
Biosystems, Rotkreuz, Switzerland) were used for real-time PCR amplification. The 
following PCR primers (Applied Biosystems) were used: leptin: Mm00434759 m1; pcsk1: 
Mm00479023_m1. Relative gene expression was obtained after normalization to 
18sRNA (Applied Biosystems), using the formula 2-ΔΔcp (22).  
 
Experiments in isolated islets 
For mouse islet isolation, pancreata were perfused via the pancreatic duct with a 
collagenase solution (Worthington, Lakewood, NJ), excised and digested in the same 
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solution at 37oC for 27 minutes. The digest was sequentially filtered through 500 μm and 
70 μm cell strainers (BD Falcon). Islets were handpicked under a microscope and 
cultured in 24-well ECM coated plates (Novamed Ltd., Jerusalem, Israel) for 40 hours in 
RPMI-1640 containing 11.1 mM glucose, 100 units/ml penicillin, 100 μg/ml streptomycin, 
2 mM glutamax, 50 μg/ml gentamycin, 10 μg/ml Fungison and 10 % FCS at a density of 
25 islets/well. To determine glucose stimulated insulin secretion islets were 
preincubated for 30 minutes in modified Krebs-Ringer bicarbonate buffer (KRB) 
containing 115 mM NaCl, 4.7 mM KCl, 2.6 mM CaCl2 2H2O, 1.2 mM KH2PO4, 1.2 mM 
MgSO4 7H2O, 10 mM HEPES, 0.5 % bovine serum albumin, pH 7.4 and 2.8 mM 
glucose. KRB was then replaced by KRB 2.8 mM glucose and collected after 1 hour 
(basal insulin release), followed by collection of 1 hour release in KRB 16.7 mM glucose 
(stimulated insulin release) or KRB 16.7 mM glucose with 100 nM GLP-1(7-36) amide 
(Bachem, Switzerland). For determination of the insulin content islet cells were extracted 
with 0.18 N HCl in 70 % EtOH. Insulin concentrations were determined using mouse 
insulin ultrasensitive mouse/rat insulin kit (Mesoscale Discovery, Rockville, MD). 
  
Ileum explants 
Terminal ileum was dissected, flushed in PBS and cut into smaller pieces of 0.5 
cm length. Explants were maintained in culture medium (Krebs buffer containing 0.1% 
BSA, 5 mM D-Glucose and 100 µM of Diprotin A (Sigma)). After 1 hour, medium was 
changed and supplemented with 15 mM D-Glucose or 0.1 µM recombinant leptin (Bio-
Techne Ltd, Abingdon, U.K.) for 2 hours. Thereafter, supernatants were collected and 
explants were snap frozen until further processing. 
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GLUTag cell culture 
GLUTag cells were grown in DMEM (1g/L glucose with L-glutamine and pyruvate) 
supplemented with 10% FBS and 1% penicillin-streptomycin. For experiments, cells 
were seeded in 12 well (200’000 cells/well) or 24 well (100’000 cells/well) plates. After 
one day, cells were fasted overnight in serum-free medium and subsequently stimulated 
with or without 0.1 µM recombinant leptin (Bio-Techne Ltd) for 6 hours. Alternatively, 
fasted GLUTag cells were treated with supernatants of isolated adipocytes for 6 hours in 
the presence or absence of neutralizing leptin antibody (0.2 µg/ml; Bio-Techne). 
 
Data analysis 
Data are presented as means ± SEM. Data were analyzed by unpaired two-tailed 
Student’s t test, one sample t test, one-way ANOVA with Newman-Keuls correction for 
multiple group comparisons or two-way ANOVA with Bonferroni multiple comparisons. 
All statistical tests were calculated using the GraphPad Prism 5.04 (GraphPad Software, 
San Diego, CA, USA). P values < 0.05 were considered to be statistically significant.  
 
 
Results 
Impaired glucose tolerance in HFD-fed gp130Δadipo mice 
To investigate a possible role of adipocyte-specific IL-6-type cytokine signaling in 
glucose metabolism, intraperitoneal glucose tolerance tests were performed in 
adipocyte-specific gp130 knockout mice (gp130Δadipo) and control littermate mice 
(gp130F/F) fed a chow or high fat diet (HFD) for twelve weeks. As previously shown,  
gp130 protein levels are reduced in isolated adipocytes but not in skeletal muscle and 
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liver of gp130Δadipo mice compared to control littermates, and body weight (4) as well as 
food intake was similar in both genotypes (Supplemental Fig. 1). As depicted in Fig. 1A 
and B, depletion of gp130 in adipocytes led to a stronger deterioration of intraperitoneal 
glucose tolerance in HFD-fed mice. In contrast, intraperitoneal insulin tolerance was 
improved in HFD-fed gp130Δadipo mice (Fig. 1C and D), confirming previous findings 
obtained from hyperinsulinemic-euglycemic clamp studies (4). Such data indicate that 
impaired glucose tolerance in knockout mice may be the result of blunted glucose-
stimulated insulin secretion. Indeed, glucose-stimulated circulating insulin levels were 
significantly lower after intraperitoneal glucose injection in HFD-fed gp130Δadipo 
compared to gp130F/F mice (Fig. 1E). To investigate whether impaired β-cell function 
may drive the observed phenotype, glucose-stimulated insulin secretion (GSIS) was 
assessed in islets ex vivo. Of note, GSIS was not impaired in islets isolated from HFD-
fed gp130Δadipo mice when compared to control littermates (Fig. 1F). Moreover, insulin 
content was higher in HFD-fed knockout compared to control mice (Supplemental Fig. 
2). Hence, deteriorated glucose-stimulated insulin levels in vivo do not result from 
defective β-cell function. Rather, impaired incretin secretion may constitute the observed 
metabolic phenotype. 
 
Reduced circulating GLP-1 levels in obese gp130Δadipo mice 
 To assess a potential involvement of impaired incretin secretion, oral glucose 
tolerance tests were performed. As depicted in Fig. 2A and B, oral glucose tolerance 
was significantly impaired in HFD-fed knockout mice, paralleled by a ~40% reduction in 
circulating insulin levels (Fig. 2C).  Of note, the difference between knockout and control 
mice was even more pronounced after oral compared to intraperitoneal glucose 
 11 
administration [~20% difference in area under the curve (AUC) between HFD-fed 
gp130Δadipo and control littermates after oral administration (Fig. 2B) vs. ~10% difference 
in AUC after intraperitoneal glucose injection (Fig. 1B)]. Since glucose clearance during 
oral glucose tolerance test is augmented by incretins (23), such data further support a 
role for decreased incretin secretion as a cause for impaired glucose tolerance in gp130 
knockout mice. Indeed, basal as well as glucose-stimulated levels of glucagon-like 
peptide-1 (GLP-1) were reduced by ~50% in knockout mice (Fig. 2D). Importantly, the 
GLP-1 receptor antagonist exendin 9-39 (24) blunted the difference in glucose tolerance 
between HFD-fed control and knockout mice (Figs. 2E and F). In fact, exendin 9-39 
significantly blunted AUC in gp130F/F mice (1272±57 mmol/l*min in control vs. 1500±51 
mmol/l*min in exendin 9-39 treated mice; p<0.05) but not in gp130Δadipo mice (1507±34 
mmol/l*min in control vs. 1567±34 mmol/l*min in exendin 9-39 treated mice; p=0.23). 
Besides affecting oral glucose tolerance, exendin 9-39 treatment abrogated impaired 
intraperitoneal glucose tolerance in gp130Δadipo mice (Fig. 2G), suggesting that reduced 
basal GLP-1 levels (Fig. 2D) contributed to impaired intraperitoneal glucose tolerance in 
untreated mice (Fig. 1A and B). Of note, ex vivo stimulation of pancreatic islets with high 
glucose concentration in combination with GLP-1 revealed similar degrees of insulin 
secretion in HFD-fed gp130F/F and gp130Δadipo mice (Fig. 2H) indicating similar GLP-1 
sensitivity of β-cells. Taken together, adipocyte-specific depletion of IL-6-type cytokine 
signaling reduces GLP-1 release in in HFD-fed mice thereby impairing glucose 
tolerance.  
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IL-6 signaling in adipocytes contributes to obesity-induced circulating leptin levels 
 Reduced circulating GLP-1 levels in HFD-fed gp130Δadipo mice may result from 
enhanced degradation by dipeptidyl peptidase IV (DPP IV) that is increasingly released 
from adipose tissue in obesity (10; 25). However, plasma DPP IV levels were similar in 
HFD-fed gp130F/F and gp130Δadipo mice (Supplemental Fig. 3), indicating that IL-6-type 
cytokine signaling did not affect circulating DPP IV levels and, hence, was not 
responsible for blunted GLP-1 levels in knockout mice. Circulating GLP-1 derives almost 
completely from enteroendocrine L cells  (12). Thus, reduced circulating GLP-1 levels in 
gp130 knockout mice may result from blunted intestinal secretion. Indeed, glucose-
stimulated GLP-1 secretion from intestinal explants harvested from HFD-fed gp130Δadipo 
mice was reduced (Fig. 3A), whereas its release from islets isolated from HFD-fed 
knockout mice remained unaffected (Supplemental Fig. 4). Hence, reduced circulating 
GLP-1 levels in HFD-fed gp130Δadipo mice resulted from its blunted release from 
enteroendocrine cells.  
Recently, different adipose-derived circulating factors were shown to affect GLP-1 
release from intestinal cells. In fact, circulating IL-6 was shown to stimulate GLP-1 
secretion thereby enhancing glucose-stimulated insulin secretion (26). Moreover, the 
two adipokines adiponectin and leptin were reported to induce GLP-1 secretion from 
intestinal L cells (9; 27). As depicted in Supplemental Fig. 5, circulating IL-6 and 
adiponectin levels were similar between HFD-fed gp130F/F and gp130Δadipo mice. In 
contrast, plasma leptin levels were reduced by ~40% in gp130Δadipo mice (Fig. 3B) 
despite similar body weight (4), potentially contributing to their reduced GLP-1 levels. To 
analyze the impact of IL-6-cytokine signaling on leptin production in adipocytes, its 
expression and release were analyzed in isolated adipocytes of chow- and HFD-fed 
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knockout and control mice. As expected, HFD induced leptin mRNA expression in and 
release from adipocytes of control mice (Fig. 3C and D). Importantly, leptin release from 
adipocytes was significantly blunted in HFD-fed knockout mice (Fig. 3D), whereas its 
expression was unchanged (Fig. 3C). In addition, leptin content in isolated adipocytes of 
HFD-fed mice was similar between the genotypes (Fig. 3E). Hence, IL-6-type cytokine 
signaling in adipocytes affects leptin release but not its transcription and protein 
synthesis. We next wanted to investigate which member of the IL-6-type cytokine family 
mediated the effect on leptin release. To this end, isolated adipocytes of chow-fed 
gp130F/F and gp130Δadipo mice were incubated with the IL-6-type cytokine family 
members ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), IL-6, IL-11, LIF or 
oncostatin M (OSM), which were previously suggested to affect leptin production or 
were suggested as potential targets to treat obesity (5-8; 28). While CNTF, CT-1, IL-11, 
LIF and OSM had no significant effect on leptin release, IL-6 stimulated leptin secretion 
in isolated adipocytes gp130-dependently (Fig. 3F). Taken together, IL-6 induced leptin 
release from adipocytes thereby contributing to elevated circulating leptin levels in HFD-
fed mice.  
 
Leptin induces Pcsk1 expression and GLP-1 release in enteroendocrine cells 
Leptin induces GLP-1 release from the enteroendocrine cell line GLUTag cells (9; 
29). Such release of GLP-1 is regulated by PC1/3 in intestinal cells (10; 13). Indeed, 
expression of proprotein convertase subtilisin/kexin type 1 (Pcsk1), the gene encoding 
PC1/3 (13), was significantly increased by leptin treatment (Fig. 4A). Importantly, leptin 
also stimulated Pcsk1 expression in L cell-rich ileum (14) explants harvested from HFD-
fed gp130F/F mice (Fig. 4B). Next, experiments in GLUTag cells that were incubated with 
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supernatant harvested from isolated adipocytes were performed to further explore the 
proposed adipo-enteroendocrine axis driven by leptin. As shown in Fig. 4C, GLP-1 
release was significantly blunted in GLUTag cells incubated with supernatants collected 
from adipocytes of HFD-fed gp130Δadipo mice. Of note, leptin concentration was reduced 
in such supernantants as shown above (Fig. 3D). Importantly, leptin neutralization 
reversed observed difference on GLP-1 release in GLUTag cells incubated with 
supernatant collected from adipocytes (Fig. 4D) suggesting a critical role of leptin in the 
observed effect. In parallel, Pcsk1 expression was reduced (Fig. 4E) in GLUTag cells 
incubated with supernatants collected from adipocytes of HFD-fed gp130Δadipo mice, an 
effect that was reversed upon leptin neutralization (Fig. 4F). Likewise, expression of 
Pcsk1 was reduced in the ileum of HFD-fed knockout mice (Fig. 4G). Collectively, our 
data suggest that IL-6-type cytokine signaling in adipocytes promotes intestinal GLP-1 
release leptin-dependently, probably by stimulating Pcsk1 expression.  
 
 
Discussion 
The present study suggests that adipocyte-specific IL-6-type cytokine signaling 
promotes leptin-mediated GLP-1 release from enteroendocrine cells in obesity thereby 
improving glucose-stimulated insulin release and glucose tolerance (Fig. 5). Such notion 
is based on the following findings: i. gp130 depletion specifically in adipocytes impaired 
glucose tolerance and reduced circulating leptin, GLP-1 and insulin levels in HFD-fed 
mice; ii. GLP-1 secretion is reduced leptin-dependently from enteroendocrine cells 
incubated with supernatant collected from gp130-depleted adipocytes. 
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Reduced GLP-1 release from enteroendocrine cells in adipocyte-specific gp130 
knockout mice may result from reduced Pcsk1 expression, the gene encoding PC1/3 
controlling GLP-1 production (10; 13). Leptin was previously reported to enhance Pcsk1 
expression in neuronal cells (30). In HFD-fed gp130Δadipo mice, intestinal Pcsk1 
expression was lower compared to control littermates and was associated with 
significantly lower circulating leptin levels. Moreover, supernatant collected from isolated 
adipocytes regulated Pcsk1 expression in GLUTag cells in a leptin-dependent manner, 
and recombinant leptin stimulated Pcsk1 expression in GLUTag cells as well as in ileum 
explants of HFD-fed mice. Of note, the role of intestinal GLP-1 in glucose homeostasis 
has recently been questioned suggesting that pancreatic GLP-1 may be more important 
for glucose homeostasis (14). Indeed, we did not find diminished GLP-1 release from 
islets isolated from HFD-fed knockout mice. Hence, our data indicate that reduced 
intestinal rather than pancreatic GLP-1 release affects glucose-stimulated insulin 
secretion and, consequently, glucose homeostasis in gp130Δadipo mice. Although we 
cannot rule out a role of pancreatic GLP-1, our data clearly support an important role of 
intestinal GLP-1 production in glucose homeostasis. In support of an involvement of the 
incretin system in the observed metabolic phenotype in HFD-fed gp130Δadipo mice, 
insulin release and content were not reduced in islets of HFD-fed knockout mice ex vivo. 
In fact, insulin content was rather elevated in islets of gp130Δadipo mice, potentially 
mirroring reduced (GLP-1-stimulated) insulin secretion in vivo. GLP-1 sensitivity of 
isolated islets was similar between HFD-fed control and knockout mice suggesting that 
reduced circulating GLP-1 levels rather than GLP-1 resistance of β-cells cause impaired 
insulin secretion in knockout mice. In support of such notion, administration of oral 
glucose, which induces circulating GLP-1 levels in contrast to intraperitoneal glucose 
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injection, exacerbated the difference in glucose tolerance between knockout and control 
mice.  
Lack of IL-6-type cytokine signaling in adipocytes blunts circulating leptin levels 
independently of fat pad mass (4). Interestingly, reduced circulating leptin levels in 
knockout mice were paralleled by reduced leptin release from but similar mRNA 
expression in adipocytes indicating that gp130 depletion affects leptin secretion but not 
leptin transcription. Accordingly, it has been suggested that circulating signals regulate 
leptin on a post-transcriptional level, whereas the long-term nutritional status affects 
leptin mRNA expression (31). In the past, several IL-6-type cytokines were suggested to 
affect leptin production or were proposed as potential targets to treat obesity (5-8; 28). 
Here, we suggest that IL-6 contributes to obesity-induced leptin release from adipocytes, 
adding another metabolic function to the pleiotropic actions of IL-6 (32-34). In fact, 
among all tested IL-6-type cytokines only IL-6 significantly increased leptin release from 
isolated adipocytes. Consistently, treatment of HFD-fed C57BL/6 mice with an anti-IL-6 
receptor antibody reduced circulating leptin levels (35). Clearly, we cannot rule out that 
other IL-6-type family members and/or other molecules binding gp130 such as 
superantigens (36) contribute to reduced circulating leptin levels in knockout mice. In 
addition, compensatory changes in the production of other adipose-derived factors in 
knockout mice may have contributed to reduced leptin levels.  
Despite impaired glucose tolerance, insulin sensitivity was improved in HFD-fed 
gp130Δadipo mice. This observation may be explained by reduced portal FFA flux in 
knockout mice leading to blunted hepatic insulin resistance and steatosis (4). Hence, IL-
6-cytokine signaling in adipocytes may promote both protective as well as harmful 
effects on glucose metabolism (Fig. 5). Physiologically, increased IL-6-mediated release 
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of FFA and leptin from adipocytes in obesity may be interpreted as an attempt to reduce 
lipid stores by increasing lipolysis (FFA release) and by lowering lipid accumulation via 
leptin-mediated reduction of food intake. Notably, the observed leptin-mediated effect of 
IL-6 on circulating GLP-1 levels may be additive to the direct effect of IL-6 on GLP-1 
release from enteroendocrine cells (26). 
Of note, reduced circulating leptin levels in knockout mice did not significantly 
affect body weight (4), suggesting similar central leptin action between control and 
knockout mice. In agreement, food intake was similar between HFD-fed gp130F/F and 
gp130Δadipo littermates. Such finding may suggest that high fat diet feeding induces a 
central leptin resistance, while leptin-mediated signaling in the periphery (e.g. in 
intestinal cells) is less affected (37; 38). Accordingly, leptin induced Pcsk1 expression in 
the ileum of HFD-fed mice. Alternatively, decreased leptin passage across the blood-
brain-barrier in obese mice and/or local GLP-1 production in the brain (10; 37) may lead 
to unaffected GLP-1 levels in the brain of knockout mice. Clearly, further studies are 
needed to shed more light on involved mechanisms. In addition, adipocyte-specific 
depletion of gp130 in female mice may result in a different metabolic phenotype, as 
leptin secretion and the potency of GLP-1-function are sex-dependent (39). 
In conclusion, we identify a novel adipo-enteroendocrine axis driven by IL-6 in the 
regulation of glucose-stimulated insulin release and glucose tolerance in obesity. Such 
axis may sensitize pancreatic β-cells to glucose and, thus, counteract adipose tissue-
induced insulin resistance (4; 40). Moreover, it may offset carbohydrate and/or leptin 
resistance of enteroendocrine cells resulting in augmented GLP-1 levels in obesity (9; 
41-43).  
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Figure Legends 
 
Figure 1 Impaired glucose tolerance in HFD-fed gp130Δadipo mice 
Intraperitoneal glucose tolerance (ipGTT) (A and B) and insulin tolerance (ipITT) (C and 
D) tests were performed in chow and HFD-fed gp130F/F and gp130Δadipo littermate mice. 
n=6-10 for chow; n=21-31 for HFD. (E) Circulating insulin levels were assessed after 
intraperitoneal glucose injection in HFD-fed gp130F/F and gp130Δadipo mice. n=10-14. (F) 
Insulin release was assessed in isolated islets of HFD-fed gp130F/F and gp130Δadipo mice 
stimulated with 2.8 mM (basal) or 16.7 mM (glucose) glucose. n=6-11 biological 
replicates à 25 pooled islets isolated from HFD-fed gp130F/F (n=4 mice) and gp130Δadipo 
(n=3 mice). Values are expressed as mean ± SEM. F/F: gp130F/F; ∆ad: gp130Δadipo. *p < 
0.05, **p < 0.01, ***p < 0.001 (ANOVA).  
 
Figure 2 Reduced circulating GLP-1 levels in obese gp130Δadipo mice 
(A and B) Oral glucose tolerance (oGTT) test was performed in chow and HFD-fed 
gp130F/F and gp130Δadipo mice. n=4-5 for chow; n=7 for HFD. Circulating insulin (C) and 
GLP-1 (D) levels were assessed after oral glucose administration in HFD-fed gp130F/F 
and gp130Δadipo mice. n=6-8. (E and F) Oral glucose tolerance test was performed in 
HFD-fed gp130F/F and gp130Δadipo mice 15 minutes after intraperitoneal injection of 25 
nM/kg BW exendin 9-39. n=6-8. (G) Intraperitoneal glucose (ipGTT) tolerance test was 
performed in HFD-fed gp130F/F and gp130Δadipo mice 1 minute after intraperitoneal 
injection of 25 nM/kg BW exendin 9-39. n=14-15. (H) Insulin release was assessed in 
isolated islets of HFD-fed gp130F/F and gp130Δadipo mice stimulated without (basal) or 
with 100 nM GLP-1. n=6 biological replicates à 25 pooled islets isolated from HFD-fed 
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gp130F/F (n=4 mice) and gp130Δadipo (n=3 mice).  Values are expressed as mean ± SEM. 
F/F: gp130F/F; ∆ad: gp130Δadipo. *p < 0.05, **p < 0.01, ***p < 0.001 (ANOVA). 
 
Figure 3  IL-6 signaling in adipocytes contributes to obesity-induced circulating 
leptin levels 
(A) GLP-1 release was determined from ileum explants harvested from HFD-fed 
gp130F/F and gp130Δadipo mice. n=3.  (B) Leptin concentration was determined in the 
circulation of chow and HFD-fed gp130F/F and gp130adipo mice. n=5-15. Leptin release 
from (C) and mRNA expression in (D) epididymal adipocytes isolated from chow and 
HFD-fed gp130F/F and gp130adipo mice. n=3-8. (E) Leptin content was determined in 
epididymal adipocytes isolated from HFD-fed gp130F/F and gp130adipo mice. n=6-7. (F) 
Leptin release of epididymal adipocytes isolated from chow-fed gp130F/F and gp130adipo 
mice stimulated with different IL-6-type cytokines. n=4-11. Values are expressed as 
mean ± SEM. F/F: gp130F/F; ∆ad: gp130Δadipo.  #p=0.098, *p < 0.05, **p < 0.01, ***p < 
0.001 (student’s t test or ANOVA). 
 
Figure 4  Leptin induces GLP-1 release and Pcsk1 expression in enteroendocrine 
cells 
Pcsk1 mRNA expression was determined in GLUTag cells (A) or in ileum explants 
harvested from HFD-fed gp130F/F mice (B) treated with or without recombinant leptin. 
n=8-9 for GLUTag cells; n=3 for explants. GLP-1 release was determined from GLUTag 
cells treated with supernatant released from adipocytes isolated from HFD-fed gp130F/F 
and gp130adipo mice treated without (C) (n=6-7) or with (D) (n=3) neutralizing leptin 
antibody. Pcsk1 expression was determined in GLUTag cells treated with supernatant 
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released from adipocytes isolated from HFD-fed gp130F/F and gp130adipo mice treated 
without (E) (n=7) or with (F) (n=3) neutralizing leptin antibody. (G) Pcsk1 mRNA 
expression in ileum of HFD-fed gp130F/F and gp130adipo mice. n=6-7. Values are 
expressed as mean ± SEM (except for B, E and F where mRNA expression was 
normalized to untreated control or control mouse in each litter).  F/F: gp130F/F; ∆ad: 
gp130Δadipo. #p = 0.057, *p < 0.05 (Student’s t test or one sample t-test). Pcsk1: 
proprotein convertase subtilisin/kexin type 1; SN: supernatant. 
 
Figure 5  Suggested model 
Obesity-induced rise in IL-6 increase the release of FFA and leptin from adipose tissue. 
In turn, increased FFA flux to the liver induces hepatic insulin resistance and steatosis 
(4). Moreover, elevated leptin release contributes to circulating GLP-1 and insulin levels, 
thereby counteracting (hepatic) insulin resistance. 
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Food intake in HFD-fed gp130F/F and gp130adipomice
Food intake was measured in a metabolic cage unit in HFD-fed gp130F/F and gp130Δadipo mice. n=5-7. Values
are expressed as mean ± SEM.
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GLP-1 release was assessed in isolated islets of HFD-fed gp130F/F and gp130Δadipo mice. n=12 biological
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Plasma IL-6 and adiponectin in HFD-fed gp130F/F and gp130adipomice
Circulating IL-6 (A, n=5-6) and adiponectin (B, n=6) levels were assessed in HFD-fed gp130F/F and
gp130Δadipo mice. Values are expressed as mean ± SEM.
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